Industry

— Emerging data reinforce combination lipid-lowering therapy as first-line strategy for very high-risk patients, supporting the development of obicetrapib as adjunct to high-intensity statins — NAARDEN, Netherlands & MIAMI–(BUSINESS WIRE)–NewAmsterdam Pharma (NewAmsterdam Pharma), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced emerging data adding to … [Read more…]

The study evaluated the effect of the ProAir Digihaler System on asthma control versus standard of care as measured by the Asthma Control Test, and explored use of the ProAir Digihaler System to help support patient-physician interactions for asthma management versus standard of care TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a … [Read more…]

SANTA CLARA, Calif.–(BUSINESS WIRE)–#AAA–Shape Memory Medical Inc., developer of custom, proprietary shape memory polymers for the peripheral and neurovascular markets, announced the completion of patient enrollment in AAA-SHAPE, the Company’s prospective, multicenter early feasibility safety study of the IMPEDE-FX RapidFill® Device when used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair … [Read more…]

-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD … [Read more…]

-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo – – Consistent Proteinuria Reduction Seen with Secondary Endpoints – – Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) … [Read more…]

PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Monte Nido & Affiliates (“Monte Nido” or the “Company”) to funds managed by Revelstoke Capital Partners LLC. Financial terms of the transaction were not disclosed. Founded in 1996, Monte Nido is a leading … [Read more…]

Q4’22 net revenue of $1.31 billion increased 10% as reported, or 15% in constant currency, compared to Q4’21. Organic, constant-currency net revenue grew 10%, compared to Q4’21. Fiscal 2022 net revenue of $4.83 billion increased 21% as reported, or 23% in constant currency, compared to fiscal 2021. Organic, constant-currency net revenue grew 20% compared to … [Read more…]

BAUDETTE, Minn.–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg. ANI’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine® and were developed in technical collaboration with Biophore India … [Read more…]

Longer-term survival results underscoring role of KEYTRUDA® (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189) Seven-year survival from SOLO-1 and final overall survival (OS) results from PAOLA-1 highlight role of LYNPARZA® (olaparib) in first-line maintenance of advanced ovarian cancer First presentation of KEYTRUDA in combination with an antibody-drug conjugate (enfortumab … [Read more…]